AZNAZN
US • —
$184.33
P/E
27.70
PEG
0.82
FCF Yield
—
Rev Growth YoY
+9.9% YoY
Gross Margin
81.4%
Health Score
7/10
D/E Ratio
0.61
Confidence
LOW
Business Snapshot
AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialisation of prescription medicines in key therapeutic areas including oncology, cardiovascular, respiratory, and immunology. It operates in the highly competitive global pharmaceutical market, where it competes with other large multinational drugmakers through a combination of proprietary drug portfolios, extensive R&D pipelines, and regulatory exclusivities. The company's market capitalisation and revenue data are not available in this dataset, limiting the ability to assess its precise financial scale and market cap tier for this analysis. A defining characteristic of the company is its strong intellectual property moat, supported by significant R&D investment and a late-stage pipeline that underpins its long-term revenue potential.
Financial Health
The company reports a strong gross margin of 81.4%, indicating significant pricing power and efficient production, while the net margin of 17.2% suggests decent profitability after all expenses. The balance sheet appears healthy with a debt-to-equity ratio of 0.62x and a current ratio of 0.94x, indicating that while the company has manageable leverage, its short-term liquidity is slightly below 1.0x, which could imply tight working capital...
Risk Assessment
- VALUATION — P/E of 27.7x is elevated vs the sector average of 22x, indicating a premium that may not be justified by modest revenue growth.
- EARNINGS QUALITY — The company beat analyst estimates in only 1 of the last 4 quarters, suggesting low guidance credibility and a pattern of earnings misses.
- DEBT / LIQUIDITY — Current ratio of 0.94x is below the 1.0x threshold, indicating potentially tight liquidity to cover short-term obligations.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....
The company reports a strong gross margin of 81.4%, indicating significant pricing power and efficient production, while the net margin of 17.2% suggests decent profitability after all expenses. The balance sheet appears healthy with a debt-to-equity ratio of 0.62x and a current ratio of 0.94x, indicating that while the company has manageable leverage, its short-term liquidity is slightly below 1.0x, which could imply tight working capital. Free cash flow figures are unavailable, preventing an assessment of cash generation or burn; the FCF yield is also unavailable. Overall, the company demonstrates robust profitability and manageable debt, but the lack of cash flow data and a current ratio below 1.0x suggest an investor should monitor liquidity and cash conversion closely, as these factors influence dividend capacity and reinvestment flexibility.
- VALUATION — P/E of 27.7x is elevated vs the sector average of 22x, indicating a premium that may not be justified by modest revenue growth. - EARNINGS QUALITY — The company beat analyst estimates in only 1 of the last 4 quarters, suggesting low guidance credibility and a pattern of earnings misses. - DEBT / LIQUIDITY — Current ratio of 0.94x is below the 1.0x threshold, indicating potentially tight liquidity to cover short-term obligations. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives